-葡萄糖共运输体2抑制剂对系统性右心室衰竭中心室功能的影响
Ralph Ml Neijenhuis1,2, Madelien V Regeer1,2, Niki L Walker3
1Center for Congenital Heart Disease Amsterdam-Leiden (CAHAL), Leiden University Medical Center, Leiden, The Netherlands.
Open heart
|July 22, 2025
概括
在心力衰竭患者中,-葡萄糖共运输体2抑制剂 (SGLT2i) 改善了全身右心室 (sRV) 功能. 观察到sRV全球纵向菌株和部分面积变化的早期改善,尽管肺下节奏影响了长期结果.
科学领域:
- 心脏病学 心脏病学
- 心脏衰竭研究研究
- 药理干预药理干预
背景情况:
- 系统性右心室 (sRV) 衰竭对患者构成重大风险.
- -葡萄糖共运输体2抑制剂 (SGLT2i) 是sRV衰竭的潜在治疗选择.
- 这项研究研究了SGLT2i对sRV衰竭中心室功能的影响.
研究的目的:
- 为了研究SGLT2i治疗开始后sRV功能的变化.
- 评估SGLT2i对sRV全球纵向应变 (GLS) 和部分面积变化 (FAC) 的影响.
- 评估诸如年龄和节奏等因素对治疗反应的影响.
主要方法:
- 来自ACHIEVE-SGLT2i注册表的成年sRV衰竭患者的分析.
- 纳入标准:sRV衰竭诊断,SGLT2i前心声图,并在一年内进行随访.
- 主要结局:使用线性混合模型分析的sRV GLS和FAC的变化.
主要成果:
- 在SGLT2i治疗的前50天内,sRV GLS显著改善,然后稳定.
- sRV FAC也显示了最初的改善,但在肺下左心室节奏的患者中长期恶化.
- 在最初的50天内,三状环状平面的缩度显著改善,随后稳定下来.
结论:
- 在SRV衰竭患者中,SGLT2i疗法在改善静脉静脉功能方面表现出有效性.
- 观察到早期的功能改善,但肺下左心室节奏可能会对长期的sRV功能产生负面影响.
- 结果表明SGLT2i是一种有益的治疗方法,建议对节奏策略保持谨慎.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
01:29Heart Failure II: Pathophysiology
45
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
45
01:26Heart Failure Drugs: Inotropic Agents
732
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
732
01:30Heart Failure V: Medical Management
26
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
26
01:22Heart Failure Drugs: Diuretics
495
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
495
01:22Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435